
    
      The primary objective is to demonstrate improved A1c in study subjects with type 1 and type 2
      diabetes using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a
      period of 24 weeks, compared to subjects using the OneTouch Verio® Flex BGM.
    
  